



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: Protocol Development and Regulatory Compliance

DATE: December 12, 2024

RE: PROTOCOL NRG-LU004 – PERMANENT CLOSURE

Effective immediately, NRG-LU004, “Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1),” is permanently closed to accrual. As broadcasted on October 8, 2024, accrual to NRG-LU004 was temporarily suspended to evaluate the current treatment landscape for patients with PDL-1 high locally advanced disease. NRG Oncology assessed study redesign options and, due to changing landscape, the study will not reopen. It was determined a new research concept proposal is the most direct pathway for a scientifically feasible and clinically relevant study in this patient population.

This permanent closure is not related to any safety issues, and no patients have been enrolled to the study since its reopening in January 2024.

Reminders:

- Data collection and site IRB renewal for closed studies must continue until the study is terminated.
- Sites that do not have active patients on treatment must follow PMB’s guidelines for drug accountability and destruction of unused drug. See protocol section 9 for further details.

Please distribute this information to the appropriate personnel at participating affiliate institutions.